Notice: This company has been marked as potentially delisted and may not be actively trading. NantKwest (NK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NK vs. PGEN, ZIOP, CLLS, BLUE, APGE, BEAM, TARS, RXRX, IMCR, and NMRAShould you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Precigen (PGEN), ZIOPHARM Oncology (ZIOP), Cellectis (CLLS), bluebird bio (BLUE), Apogee Therapeutics (APGE), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), Recursion Pharmaceuticals (RXRX), Immunocore (IMCR), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector. NantKwest vs. Precigen ZIOPHARM Oncology Cellectis bluebird bio Apogee Therapeutics Beam Therapeutics Tarsus Pharmaceuticals Recursion Pharmaceuticals Immunocore Neumora Therapeutics Precigen (NASDAQ:PGEN) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends. Is PGEN or NK more profitable? Precigen has a net margin of -3,521.68% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Precigen-3,521.68% -123.06% -87.33% NantKwest -76,658.58%-56.06%-46.93% Which has more risk and volatility, PGEN or NK? Precigen has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Which has better earnings and valuation, PGEN or NK? NantKwest has lower revenue, but higher earnings than Precigen. NantKwest is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$6.22M39.82-$95.90M-$0.55-1.54NantKwest$40K13,326.42-$65.79M-$0.70-6.96 Do analysts rate PGEN or NK? Precigen currently has a consensus price target of $7.00, indicating a potential upside of 727.81%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in PGEN or NK? 33.5% of Precigen shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 44.9% of Precigen shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer PGEN or NK? Precigen received 161 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 67.29% of users gave Precigen an outperform vote while only 51.12% of users gave NantKwest an outperform vote. CompanyUnderperformOutperformPrecigenOutperform Votes43467.29% Underperform Votes21132.71% NantKwestOutperform Votes27351.12% Underperform Votes26148.88% Does the media refer more to PGEN or NK? In the previous week, Precigen had 14 more articles in the media than NantKwest. MarketBeat recorded 14 mentions for Precigen and 0 mentions for NantKwest. NantKwest's average media sentiment score of 0.00 beat Precigen's score of -0.01 indicating that NantKwest is being referred to more favorably in the news media. Company Overall Sentiment Precigen Neutral NantKwest Neutral SummaryPrecigen beats NantKwest on 11 of the 18 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get NantKwest News Delivered to You Automatically Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NK vs. The Competition Export to ExcelMetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$533.06M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-6.8716.1687.8613.46Price / Sales13,326.42282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book3.964.436.946.30Net Income-$65.79M-$41.63M$119.12M$225.93M NantKwest Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKNantKwestN/A$4.88-8.8%N/A+20.4%$533.06M$40,000.00-6.87160Analyst ForecastHigh Trading VolumePGENPrecigen3.7724 of 5 stars$0.88+5.7%$7.00+691.9%-30.9%$258.90M$6.22M0.00202Analyst RevisionZIOPZIOPHARM OncologyN/AN/AN/AN/A$187.12MN/A-2.01105Analyst ForecastCLLSCellectis2.4726 of 5 stars$1.83-4.2%$7.00+282.5%-38.4%$101.71M$9.19M0.00290Analyst ForecastBLUEbluebird bio2.4743 of 5 stars$0.29-2.7%$3.03+925.8%-92.1%$57.34M$29.50M-0.16323Analyst ForecastGap UpAPGEApogee Therapeutics2.4639 of 5 stars$44.30-1.6%$78.50+77.2%+149.9%$1.99BN/A0.0091BEAMBeam Therapeutics2.9285 of 5 stars$23.64-3.5%$44.91+90.0%-20.4%$1.96B$377.71M-13.91461TARSTarsus Pharmaceuticals1.8691 of 5 stars$45.97-1.3%$54.20+17.9%+166.2%$1.76B$17.45M-12.2350Analyst RevisionRXRXRecursion Pharmaceuticals2.0056 of 5 stars$5.74-5.0%$9.25+61.1%-12.0%$1.65B$44.58M0.00400Analyst ForecastOptions VolumeIMCRImmunocore3.012 of 5 stars$32.50+0.2%$69.18+112.9%-28.7%$1.63B$249.43M-33.96497Positive NewsNMRANeumora Therapeutics1.5781 of 5 stars$9.86+0.7%$21.67+119.7%-17.4%$1.59BN/A0.00108 Related Companies and Tools Related Companies PGEN Alternatives ZIOP Alternatives CLLS Alternatives BLUE Alternatives APGE Alternatives BEAM Alternatives TARS Alternatives RXRX Alternatives IMCR Alternatives NMRA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
